38.35
+0.92%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Dermapharm Holding
Its shares trade on XETRA under the ticker DMP.DE. It has been listed since 9 February 2018. In the fiscal year to 31 December 2025, it reported revenue of €1.16bn and net income of €132.4m. At that date it held total assets of €2.20bn and shareholders' equity of €694.4m.
Dermapharm Holding SE engages in the development, manufacture. The company is headquartered in Gruenwald, Bayern. The company went IPO on 2018-02-09. The firm operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. The company holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The firm offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. The company is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 9 Feb 2018
- Employees
- 2,163
- Website
- ir.dermapharm.de ↗
Leadership
Pay as last reported
- Mr. Wilhelm BeierChairman of the Supervisory Board, since 2017€80,000
- Dr. Hans-Georg FeldmeierChairman of the Management Board, Chief Executive Officer€1.4m
- Dr. Erwin KernIndependent Deputy Chairman of the Supervisory Board, since 2017€80,000
- Mr. Christof DreibholzChief Financial Officer, Chief Compliance Officer, Member of the Management Board€683,000
- Dr. Andreas EberhornChief Marketing Officer, Member of the Management Board€694,000
- Mr. Lothar LanzIndependent Member of the Supervisory Board€80,000
- Ms. Britta HambergerHead - Investor Relations and Corporate Communications, since 2021
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 53
- Environment
- 44
- Social
- 74
- Governance
- 42
- Women in the workforce
- 58.49945%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Dermapharm Holding SE has several strengths that contribute to its success in the market. These strengths include:
Weaknesses
- Despite its strengths, Dermapharm Holding SE also faces some weaknesses that may hinder its growth and competitiveness. These weaknesses include:
Opportunities
- Dermapharm Holding SE has opportunities to capitalize on to further expand its business and improve its market position. These opportunities include:
Threats
- Dermapharm Holding SE faces certain threats that could impact its business and profitability. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.